We are live on
!
Find out more
Federated Hermes Portfolio holdings
AUM
$69.6B
1-Year Est. Return
42.52%
This Fund
S&P 500
This Quarter
Est. Return
+13.69%
1 Year Est. Return
+42.52%
3 Year Est. Return
+132.48%
5 Year Est. Return
+152.58%
10 Year Est. Return
+652.43%
AUM
$53.1B
AUM Growth
+$6.76B
(+15%)
Cap. Flow
+$2.33B
Cap. Flow
% of AUM
4.39%
Top 10 Holdings %
Top 10 Hldgs %
14.65%
Holding
2,220
New
169
Increased
729
Reduced
1,033
Closed
165
Avg Time Held
21.7
quarters
Top 10 Avg Time Held
6.6
quarters
Top 20 Avg Time Held
9.9
quarters
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Zscaler
ZS
|
+$222M |
| 2 |
Palantir
PLTR
|
+$221M |
| 3 |
Alphabet (Google) Class A
GOOGL
|
+$213M |
| 4 |
FirstEnergy
FE
|
+$189M |
| 5 |
Broadcom
AVGO
|
+$174M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Bristol-Myers Squibb
BMY
|
+$383M |
| 2 |
Philip Morris
PM
|
+$280M |
| 3 |
Entergy
ETR
|
+$207M |
| 4 |
Paychex
PAYX
|
+$206M |
| 5 |
Gilead Sciences
GILD
|
+$201M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 22.81% |
| 2 | Healthcare | 14.57% |
| 3 | Financials | 13.43% |
| 4 | Industrials | 10.29% |
| 5 | Consumer Discretionary | 9.91% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
1851
MongoDB
MDB
$30.6B
| $7.56K | ﹤0.01% |
36
-9,995
| -100% | -$1.85M |
2025 Q1
1 quarter
|
|
1852
Actinium Pharmaceuticals
ATNM
$34M
| $7.45K | ﹤0.01% |
5,321
-218
| -4% | -$326 |
2024 Q3
3 quarters
|
|
1853
DELISTED
Golden Ocean Group
GOGL
| $7.42K | ﹤0.01% |
1,013
-316
| -24% | -$2.4K |
2024 Q4
2 quarters
|
|
1854
ACI Worldwide
ACIW
$5.18B
| $7.3K | ﹤0.01% |
159
-54
| -25% | -$2.65K |
2025 Q1
1 quarter
|
|
1855
Zevra Therapeutics
ZVRA
$664M
| $7.26K | ﹤0.01% |
+824
| New | +$6.69K |
2025 Q2
0 quarters
|
|
1856
LifeVantage
LFVN
$75.5M
| $7.19K | ﹤0.01% |
+550
| New | +$7.11K |
2025 Q2
0 quarters
|
|
1857
Vera Bradley
VRA
$151M
| $7.16K | ﹤0.01% |
3,239
+2,759
| +575% | +$5.69K |
2025 Q1
1 quarter
|
|
1858
Anterix
ATEX
$1.66B
| $7.11K | ﹤0.01% |
277
-58
| -17% | -$1.7K |
2024 Q3
3 quarters
|
|
1859
VirTra
VTSI
$30.9M
| $6.85K | ﹤0.01% |
969
+567
| +141% | +$2.98K |
2025 Q1
1 quarter
|
|
1860
DELISTED
CSG Systems International
CSGS
| $6.79K | ﹤0.01% |
104
-46
| -31% | -$2.87K |
2024 Q3
3 quarters
|
|
1861
TransUnion
TRU
$12.6B
| $6.78K | ﹤0.01% |
77
-501
| -87% | -$41.8K |
2023 Q4
6 quarters
|
|
1862
Merit Medical Systems
MMSI
$5.36B
| $6.64K | ﹤0.01% |
71
-239
| -77% | -$22.6K |
2024 Q1
5 quarters
|
|
1863
Chesapeake Utilities
CPK
$3.26B
| $6.61K | ﹤0.01% |
55
-58
| -51% | -$7.3K |
2018 Q3
27 quarters
|
|
1864
Fennec Pharmaceuticals
FENC
$372M
| $6.55K | ﹤0.01% |
+789
| New | +$5.4K |
2025 Q2
0 quarters
|
|
1865
Perdoceo Education
PRDO
$2.11B
| $6.5K | ﹤0.01% |
199
-158
| -44% | -$4.68K |
2024 Q3
3 quarters
|
|
1866
Eagle Bancorp Montana
EBMT
$167M
| $6.5K | ﹤0.01% |
+390
| New | +$6.54K |
2025 Q2
0 quarters
|
|
1867
Patrick Industries
PATK
$2.04B
| $6.46K | ﹤0.01% |
70
-38
| -35% | -$3.23K |
2017 Q1
33 quarters
|
|
1868
BARK
BARK
$72.8M
| $6.45K | ﹤0.01% |
367
+80
| +28% | +$1.84K |
2023 Q4
6 quarters
|
|
1869
Nkarta
NKTX
$158M
| $6.32K | ﹤0.01% |
3,805
-1,561
| -29% | -$2.86K |
2025 Q1
1 quarter
|
|
1870
DELISTED
Heidrick & Struggles
HSII
| $6.32K | ﹤0.01% |
138
+81
| +142% | +$3.4K |
2025 Q1
1 quarter
|
|
1871
Electromed
ELMD
$230M
| $6.16K | ﹤0.01% |
280
+31
| +12% | +$673 |
2024 Q2
4 quarters
|
|
1872
DELISTED
ProAssurance
PRA
| $6.12K | ﹤0.01% |
268
-68
| -20% | -$1.57K |
2020 Q2
20 quarters
|
|
1873
UBS Group
UBS
$147B
| $6.09K | ﹤0.01% |
180
| – | – |
2023 Q3
7 quarters
|
|
1874
iShares MSCI Japan Value ETF
EWJV
$769M
| $5.94K | ﹤0.01% |
171
| – | – |
2022 Q1
13 quarters
|
|
1875
ClearPoint Neuro
CLPT
$314M
| $5.91K | ﹤0.01% |
+495
| New | +$6.23K |
2025 Q2
0 quarters
|
|
Similar funds
Federated Hermes's Q2 2025 Portfolio in Review
As of Q2 2025, Federated Hermes held 2,220 positions worth $53.1B, up 15% from $46.4B the previous quarter. Its ten largest holdings account for 15% of the portfolio.
Federated Hermes deployed $2.33B of net new capital in Q2 2025, opening 169 new positions and adding to 729 existing holdings. Its largest new stake was Genuine Parts: 882,160 shares worth $107M.
By sector, the portfolio is most concentrated in Technology at 23% of assets, up from 20% a quarter earlier, followed by Healthcare and Financials.
On the sell side, the largest reduction was Bristol-Myers Squibb, an estimated $383M trimmed.
- Federated Hermes's largest Q2 2025 buy was Genuine Parts: 882,160 shares worth $107M.
- Federated Hermes added most to Zscaler in Q2 2025, an estimated $222M increase.
- Federated Hermes's biggest Q2 2025 reduction was Bristol-Myers Squibb, cutting an estimated $383M.
- Federated Hermes fully exited Regulus Therapeutics in Q2 2025, selling an estimated $39.2M.
- Federated Hermes's ten largest holdings make up 15% of its $53.1B portfolio in Q2 2025.
- Federated Hermes opened 169 new positions and closed 165 in Q2 2025.
- Federated Hermes's portfolio value rose 15% quarter-over-quarter to $53.1B.
Based on Federated Hermes's 13F filing for Q2 2025, filed 13 Aug 2025.